Upstream Bio’s (UPB) Buy Rating Reiterated at HC Wainwright

HC Wainwright restated their buy rating on shares of Upstream Bio (NASDAQ:UPB) in a report published on Wednesday,Benzinga reports. HC Wainwright currently has a $36.00 price target on the stock. HC Wainwright also issued estimates for Upstream Bio’s FY2028 earnings at ($3.17) EPS, FY2029 earnings at ($3.64) EPS and FY2030 earnings at ($3.70) EPS.

A number of other research firms also recently issued reports on UPB. Wall Street Zen downgraded shares of Upstream Bio from a “sell” rating to a “strong sell” rating in a research note on Saturday, August 15th. JPMorgan Chase & Co. upped their target price on Upstream Bio from $8.00 to $9.00 and gave the stock a “neutral” rating in a report on Friday, August 14th. Mizuho decreased their target price on Upstream Bio from $51.00 to $50.00 and set an “outperform” rating for the company in a research report on Thursday, May 14th. Weiss Ratings upgraded Upstream Bio from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Monday, August 17th. Finally, Truist Financial lowered their target price on Upstream Bio to $25.00 and set a “buy” rating for the company in a research note on Tuesday, August 11th. Four investment analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, Upstream Bio currently has an average rating of “Hold” and an average price target of $29.67.

Upstream Bio Stock Down 1.2%

NASDAQ:UPB opened at $6.01 on Wednesday. The firm’s fifty day simple moving average is $6.94 and its 200 day simple moving average is $7.90. The stock has a market cap of $329.17 million, a P/E ratio of -2.07 and a beta of 1.28. Upstream Bio has a twelve month low of $5.77 and a twelve month high of $33.68.

Upstream Bio (NASDAQ:UPB) last issued its quarterly earnings data on Tuesday, August 11th. The company reported ($0.73) EPS for the quarter, topping the consensus estimate of ($0.74) by $0.01. Upstream Bio had a negative net margin of 4,955.67% and a negative return on equity of 48.40%. The business had revenue of $0.77 million during the quarter, compared to analyst estimates of $0.56 million. On average, analysts expect that Upstream Bio will post -2.86 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of large investors have recently bought and sold shares of the business. BlackRock Inc. bought a new stake in Upstream Bio during the second quarter worth about $25,973,000. Norges Bank bought a new position in shares of Upstream Bio during the fourth quarter valued at approximately $78,264,000. UBS Group AG lifted its holdings in shares of Upstream Bio by 563.4% during the fourth quarter. UBS Group AG now owns 1,806,243 shares of the company’s stock valued at $49,039,000 after purchasing an additional 1,533,972 shares during the last quarter. Janus Henderson Group PLC purchased a new position in shares of Upstream Bio during the fourth quarter valued at approximately $41,423,000. Finally, Y Intercept Hong Kong Ltd boosted its position in shares of Upstream Bio by 2,049.2% in the 1st quarter. Y Intercept Hong Kong Ltd now owns 1,000,631 shares of the company’s stock worth $9,006,000 after purchasing an additional 954,072 shares in the last quarter.

Upstream Bio Company Profile

Upstream Bio, Inc is a clinical-stage biotechnology company focused on the development of next-generation prophylactic vaccines and immuno-oncology therapies. Leveraging a proprietary viral vector platform, the company aims to deliver optimized antigen payloads that stimulate robust and durable immune responses against both infectious diseases and cancer targets. Upstream Bio’s approach emphasizes safety, manufacturability and potential for rapid scale-up to address emerging public health challenges.

The company’s research and development pipeline includes multiple viral vector-based candidates in early clinical and preclinical stages.